Filing scope and business context
Entity mismatch: The supplied filing is Check-Cap Ltd.’s Form 20-F, not a filing for Mbody AI Ltd. It is an audited annual report for the fiscal year ended December 31, 2020—not a standalone 2020 Q4 report. Financial statements use U.S. GAAP and U.S. dollars.
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan, an ingestible, ultra-low-dose X-ray system intended to detect colorectal polyps without bowel preparation or sedation. The company had no product revenue and reported no specific commercial launch date.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense, net | $10.008 million | $10.474 million |
| General and administrative expense | $3.924 million | $3.595 million |
| Operating loss | $13.932 million | $14.069 million |
| Net loss | $13.846 million | $13.836 million |
| Basic and diluted loss per share | $0.46 | $1.73 |
| Net cash used in operations | $13.113 million | $12.843 million |
| Cash and cash equivalents at year-end | $7.703 million | $7.685 million |
| Short-term bank deposits at year-end | $10.079 million | None reported |
| Working capital at year-end | $15.436 million | $5.633 million |
| Total assets / shareholders’ equity | $19.638 million / $16.378 million | $9.429 million / $6.234 million |
FY 2020 financing cash flow was $23.582 million, principally from equity offerings and a warrant-exercise transaction; investing cash flow was an outflow of $10.451 million, mainly reflecting purchases of short-term deposits. The balance sheet shows no conventional borrowings. Reported liabilities include operating lease obligations and a $154,000 royalties provision; the company also disclosed contingent royalty obligations to the IIA of approximately $6.1 million and to the BIRD Foundation of approximately $185,000.
Changes, developments, and outlook
- Net loss was broadly unchanged year over year. R&D expense fell 4.4%, mainly because 2019 included higher clinical-study costs; G&A expense rose 9.2%. Lower interest income contributed to finance income declining to $86,000 from $233,000.
- Share count increased substantially through 2020 financings: 46,239,183 ordinary shares were outstanding at December 31, 2020, compared with 8,272,908 a year earlier. During Q1 2021, warrant exercises issued a further 24,204,682 shares and generated approximately $19.24 million gross proceeds; the filing reports 70,448,422 shares outstanding as of March 16, 2021.
- Management estimated cash resources would fund operations through July 2022, but said additional financing would be needed for clinical development, regulatory work, manufacturing scale-up, and commercialization. The auditor included a going-concern explanatory paragraph, citing recurring losses and the need for additional funding. Without timely financing, management may need to reduce spending, delay trials, license or sell assets, seek an acquisition, or cease operations.
- The FDA approved the IDE for the planned U.S. pivotal study in March 2021, after year-end. Management planned to start the study in late 2021, subject to funding and required approvals, and anticipated a direct de novo submission in late 2022 or early 2023 if the study succeeded. The FDA granted C-Scan Breakthrough Device designation in February 2021; this does not itself constitute marketing approval.
- Prior study results were mixed and based on limited samples. The 2017 study reported 44% sensitivity and 89% specificity in 45 evaluable subjects. A 2019 study reported 76% sensitivity for polyps at least 10 mm and 82% specificity in 90 evaluable subjects. The U.S. pilot had 28 evaluable patients and was not designed for statistical significance.
- COVID-19 temporarily suspended clinical studies and disrupted operations in 2020; salary reductions and unpaid leave were temporary, and salaries were restored as operations approached normal levels. Further pandemic effects remained uncertain.
Risks, contingencies, and unusual items
- Clinical and regulatory risk: U.S. commercialization depends on pivotal-study results and FDA clearance or approval. The FDA could require the more demanding PMA route. Existing European CE certification and Israeli authorization require ongoing regulatory work, including transition to the EU MDR framework.
- Financing and dilution: Continued losses and dependence on external capital create going-concern risk. Equity and warrant transactions materially expanded the share count; further financing could dilute existing holders.
- Execution and supply: The company has limited commercial manufacturing capacity and relies on single-source suppliers for key components, including the X-ray source. The identified supplier agreement was due to expire December 31, 2021; an in-house production line was planned but not assured.
- Product adoption and reimbursement: The company has no sales or established commercialization track record. Market acceptance, reimbursement, distribution partners, and patient and physician adoption are unproven. U.S. Medicare, Medicaid, and commercial coverage for colon capsule screening was not established.
- Other exposures: The radioactive capsule raises licensing, safety, and disposal issues; U.S. regulatory discussions indicated capsules could not then be discarded in the sanitary sewer after use. Israeli government grants impose royalty and domestic-manufacturing or technology-transfer restrictions. Currency movements also affect expenses; the company used foreign-exchange collars.
- Post-year-end intellectual property item: In March 2021, Check-Cap licensed University of Missouri patents claimed to cover background C-Scan intellectual property, agreeing to per-unit royalties and an aggregate cap. The filing text gives the cap inconsistently as $15 million in the body and $15,000 thousand in the financial-statement note; verify the executed agreement.
- The company disclosed no material litigation and no material off-balance-sheet arrangements. Management stated disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.
Investor verification priorities
- Confirm the issuer identity: this filing is for Check-Cap Ltd., not Mbody AI Ltd., and covers FY 2020 rather than Q4 alone.
- Reconcile liquidity and runway using year-end cash, short-term deposits, restricted cash, and the approximately $19.24 million of Q1 2021 warrant proceeds; confirm current burn rate and financing needs.
- Track pivotal-trial launch, enrollment, results, and FDA pathway, while distinguishing Breakthrough Device designation and IDE authorization from marketing approval.
- Review share-count dilution, outstanding warrants and options, and any subsequent capital raises.
- Verify C-Scan supplier continuity, manufacturing scale-up, radioactive-material licensing and disposal requirements, reimbursement prospects, and the University of Missouri license royalty terms.